Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 3Lymphoma 3Recurrence 2Neoplasms 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, B-Cell, Marginal Zone 2Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Melanoma 1Leukemia 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Cyclophosphamide 17Dexamethasone 15Bortezomib 14fludarabine phosphate 12Melphalan 12Lenalidomide 10fludarabine 9Filgrastim 8pomalidomide 7Tacrolimus 7Peripheral Blood Stem Cell Transplantation 7Rituximab 6Radiotherapy 6Etoposide 6Whole-Body Irradiation 5Cord Blood Stem Cell Transplantation 5Calcium Dobesilate 5Busulfan 5Antilymphocyte Serum 5sargramostim 4Sirolimus 4Panobinostat 4Mycophenolic Acid 4Methylprednisolone 4Cyclosporine 4carfilzomib 3Vorinostat 3Stem Cell Transplantation 3Prednisone 3Methotrexate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms, Plasma Cell × marizomib × Clear all
NCT02103335 2017-11-22

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

Celgene

Phase 1 Completed
38 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡